- Advertisement -
Eli Lilly has established itself as the market leader in obesity drugs in Europe, Asia and the Middle East and expects to replicate its US dominance globally, the company’s international president told Reuters on Wednesday. Patrik Jonsson said that the drugmaker is applying a consumer-focused commercial strategy similar to its US approach, including partnerships with telehealth and digital platforms to reach patients who are mainly paying for weight-loss drugs out-of-pocket, from Britain…
